Biosimilars in allergic diseases

Current Opinion in Allergy and Clinical Immunology

Volumn 16, Issue 1, 2016, Pages 68-73

  Ferrando, Matteo ^a   Bagnasco, Diego ^a   Braido, Fulvio ^a   Varricchi, Gilda ^b   Canonica, Giorgio W ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Asthma; Biologics; Biosimilars; Precision medicine; Respiratory allergic diseases

Indexed keywords

ABATACEPT; ADALIMUMAB; ALLERGEN; BIOSIMILAR AGENT; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LIGELIZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; PITRAKINRA; QUILIZUMAB; RITUXIMAB;

ALLERGIC DISEASE; ASTHMA; COST CONTROL; DRUG INDUSTRY; DRUG MARKETING; HEALTH CARE COST; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; ANIMAL; ECONOMICS; HYPERSENSITIVITY; IMMUNOLOGY;

ANIMALS; BIOSIMILAR PHARMACEUTICALS; HUMANS; HYPERSENSITIVITY;

EID: 84952862607     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000226     Document Type: Review

References (57)

1. Braido F, Holgate S, Canonica GW. From 'blockbusters' to 'biosimilars': An opportunity for patients, medical specialists and healthcare providers. Pulm Pharmacol Ther 2012; 25:483-486.
2. Pharma 2020: The vision. Which path you will take? http://www.pwc.com/gx/en/industries/pharmaceuticals-life-sciences/pharma-2020/pharma-2020-vision-path.html [Accessed 14 October 2015].
3. Li EC, Abbas R, Jacobs IA, Yin D. Considerations in the early development of biosimilar products. Drug Discov Today 2015; 20 (Suppl 2):1-9.
4. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs 2011; 3:209-217.
5. Lubenau H, Bias P, Maly AK, et al. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009; 23:43- 51.
6. Visser J, Feuerstein I, Stangler T, et al. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2013; 27:495-507.
7. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 2004; 3:43-47.
8. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008; 19:411-419.
9. Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006; 21 (Suppl 5):13-16.
10. Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res 2007; 30:267-272.
11. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241-3248.
12. Duerden M. Prescribing advice needed for new biosimilar biological drugs. Prescriber 2007; 18:1-2.
13. Reingold SC, Steiner JP, Polman CH, et al. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology 2009; 73:552- 559.
14. Malik NN. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol 2009; 6:550-552.
15. Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J Allergy Clin Immunol 2007; 120:1269-1275.
16. Wenzel SE. Asthma phenotypes: The evolution from clinical to molecular approaches. Nat Med 2012; 18:716-725.
17. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: The next steps toward personalized care. J Allergy Clin Immunol 2015; 135:299-310.
18. De Ferrari L, Chiappori A, Bagnasco D, et al. Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? Exp Opin Respir Med. 2015.
19. Hoshino M, Ohtawa J. Effects of adding omalizumab, an antiimmunoglobuline antibody, on airway wall thickening in asthma. Respiration 2012; 83:520e8.
20. Riccio AM, Dal Negro RW, Micheletto C, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patient. Int J Immunopathol Pharmacol 2012; 25:475-84.
21. Gauvreau GM, Harris JM, Boulet LP, et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med 2014; 6:243-85.
22. Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 2014; 44:1371-1385.
23. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies. Lancet 2007; 370:1422-1431.
24. Slager RE, Otulana BA, Hawkins GA, et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor a antagonist. J Allergy Clin Immunol 2012; 130:516- 522.
25. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-84.
26. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985-93.
27. Castro M, Mathur S, Hargreave F, et al., Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184:112.
28. Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010; 125:1237- 1244.
29. Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010; 125:1344-1353.
30. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088-98.
31. Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: A randomised, doubleblind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015; 3:692-701.
32. IMS MIDAS Biosimilars, IMS Health, 2010. 2011.
33. CaPGemini Consulting and DVFA 2010, Biosimilar series: Forecast analysis, Datamonitor June 2009; Biosimilars 101, Credit Suisse, August 2009.
34. Ahmed I, Kaspar B, Sharma U. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clin Ther 2012; 34:400-419.
35. Taylor P, Negotiating the emerging biosimilars landscape. Key developments in the regulatory environment, Business Insights, 2008.
36. Knezevic I, Griffiths E. Biosimilars: global issues, national solutions. Biologicals 2011; 39:252-255.
37. IGES presentation according to NVI-Insight Health. http://www.dvfa.de/fi leadmin/downloads/Publikationen/Fachbuecher/dvfa-biosimilars-2010.pdf. [Accessed 14 October 2015].
38. Shapiro RJ. The potential American market for generic biological treatments and the associated cost savings. 2008. http://www.insmed.com/pdf/Biogeneric-Savings.pdf. [Accessed 14 October 2015].
39. Howrey/CAP Analysis, The Inflated Projections of Potential Cost Savings from Follow-On Biologics: An Analysis of the Express Scripts and Engel & Novitt Reports. 2007. http://www.howrey.com/files/News/6efa58d8-75a8-49e0-ac0f-512f45769c77/Presentation/NewsAttachment/13ce02b8-b57f-4f2f-b682-4d79c22d578a/Biologics%20White%20Paper%205-2-07.pdf [Accessed 14 October 2015].
40. Ahlstrom A, King R, Brown R, et al. Modeling federal cost savings from followon biologics, Avalere Health L.L.C. 2007. http://www.avalerehealth.net/research/docs/Modeling-Budgetary-Impact-of-FOBs.pdf [Accessed 14 October 2015].
41. Congressional Budget Office, Cost Estimate S. 1695 Biologics Price Competition and Innovation Act of 2007. 2008. http://www.cbo.gov/ftpdocs/94xx/doc9496/s1695.pdf. [Accessed 14 October 2015].
42. Dudzinski DM, Kesselheim AS. Scientific and legal viability of follow-on protein drugs. N Engl J Med 2008; 358:843-849.
43. S1695: Biologics Price Competition and Innovation Act of 2007. Congressional Budget Office cost estimate. http://www.cbo.gov/ftpdocs/94xx/doc9496/s1695.pdf. [Accessed 14 October 2015].
44. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. http://www.ema.europa.eu/pdfs/human/biosimilar/043704en.pdf. [Accessed 14 October 2015].
45. World Health Organization (2009) Guidelines on evaluation of similar biotherapeutic products (SBPs). http://www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf. [Accessed 14 October 2015].
46. US Food and Drug Administration (2012) Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformatin/Guidances/UCM291134.pdf. [Accessed 14 October 2015].
47. The Biologics Price Competition and Innovation Act of 2009. HR 3590-686. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf [Accessed 14 December 2011].
48. [Accessed 14 October 2015].
49. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on immunogenicity assessment of biotechnology- derived therapeutic proteins. http://www.emea.europa.eu/pdfs/human/biosimilar/1432706enfin.pdf. [Accessed 28 January 2011].
50. ICH Harmonised Tripartite Guideline. Specifications: Test procedures and acceptance criteria for biotechnological/biological products Q6B. 1999. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002824.pdf. [Accessed 4 August 2011].
51. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology- derived proteins as active substance: quality issues. http://www.emea.europa.eu/pdfs/human/biosimilar/4934805en.pdf. [Accessed 9 August 2011].
52. Kresse GB. Biosimilars: science, status, and strategic perspective. Eur J Pharm Biopharm 2009; 72:479-486.
53. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008; 19:411-419.
54. Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310-312.
55. International Conference on Harmonization. ICH armonized Tripartite Guideline. Comparability of biotechnological/biological products subject to changes in their manufacturing process. 2004. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Quality/Q5E/Step4/Q5E-Guideline.pdf. [Accessed 14 October 2015].
56. US Food and Drug Administration. Guidance for industry. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf. [Accessed 14 October 2015].
57. US Food and Drug Administration. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. [Accessed 14 October 2015].